Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects

    May 2019 in “ Journal of dermatological treatment ”
    András Bánvölgyi, Pálma Anker, Kende Lőrincz … Norbert Wikonkál
    Studysummary This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Managing Adverse Events Associated with Vismodegib in the Treatment of Basal Cell Carcinoma Future oncology · 2016
    2. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma ˜The œoncologist · 2016
    3. Modulation of Hair Growth with Small Molecule Agonists of the Hedgehog Signaling Pathway Journal of Investigative Dermatology · 2005

    Related research 1

    1. Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects Journal of dermatological treatment · 2019